What is the most common cause of a mildly elevated alanine aminotransferase (ALT) level of approximately 71 U/L in an adult?

Most Common Cause of ALT 71 U/L

The most common cause of a mildly elevated ALT of 71 U/L is nonalcoholic fatty liver disease (NAFLD), which accounts for the majority of mild aminotransferase elevations in developed countries. 1

Understanding the Elevation

An ALT of 71 U/L represents a mild elevation (defined as <5 times the upper reference limit), which falls into the most common category of aminotransferase abnormalities seen in primary care. 1 This level is approximately 2-3 times the upper limit of normal, depending on sex-specific reference ranges (normal ALT: 29-33 IU/L for men, 19-25 IU/L for women). 1

Primary Differential Diagnosis

Most Common Causes (in order of frequency):

• Nonalcoholic fatty liver disease (NAFLD): Prevalence of 20-30% in the general population, increasing to 70% with obesity and 90% with diabetes mellitus. 1 This is the leading cause of chronic liver disease in developed countries. 1

• Alcohol-induced liver disease: The second most common cause of fatty liver disease, though the AST:ALT ratio is typically >2 in alcoholic liver disease versus <1 in NAFLD. 1

Uncommon Causes:

• Drug-induced liver injury 1
• Chronic hepatitis B 1
• Chronic hepatitis C 1
• Hereditary hemochromatosis 1

Rare Causes:

• Alpha-1 antitrypsin deficiency 1
• Autoimmune hepatitis 1
• Wilson disease 1

Clinical Approach Algorithm

Step 1: Assess Metabolic Risk Factors

Evaluate for features of metabolic syndrome and insulin resistance: 2

• Waist circumference (>40 inches men, >35 inches women)
• Blood pressure (≥130/≥85 mm Hg)
• Fasting lipids (triglycerides ≥150 mg/dL, HDL <40 mg/dL men/<50 mg/dL women)
• Fasting glucose ≥100 mg/dL or diabetes diagnosis
• Body mass index ≥25 kg/m²

Step 2: Rule Out Secondary Causes

Obtain detailed history regarding: 2

• Alcohol consumption (≥14 drinks/week women, ≥21 drinks/week men)
• Medications, vitamins, supplements, and herbal products
• Risk factors for viral hepatitis (injection drug use, transfusions, sexual exposure)
• Family history of liver disease

Step 3: Initial Laboratory Evaluation

Order the following tests: 3, 4

• Hepatitis B surface antigen (HBsAg)
• Hepatitis C antibody (anti-HCV)
• Complete blood count with platelets
• Serum albumin
• Prothrombin time/INR
• Fasting lipid panel
• Fasting glucose or HbA1c
• Iron studies (serum iron, total iron-binding capacity, ferritin)

Step 4: Risk Stratification for Fibrosis

Calculate FIB-4 score as the preferred initial noninvasive test for assessing liver fibrosis risk. 2 If FIB-4 >1.3, proceed with second-level testing such as vibration-controlled transient elastography (VCTE). 2

Important Clinical Caveats

Common Pitfalls to Avoid:

• Do not assume normal ALT excludes significant liver disease: Up to 50% of patients with NAFLD and even those with clinically significant fibrosis (F2) may have ALT <40 U/L. 2 Normal aminotransferases do not exclude NAFLD or advanced fibrosis. 5

• Do not rely solely on imaging for diagnosis: In high-risk groups (obesity, diabetes, metabolic syndrome), the pretest probability of NAFLD is >70%, making it reasonable to proceed with risk stratification without requiring ultrasound confirmation of steatosis. 2

• Consider sex-specific reference ranges: Updated thresholds suggest true normal ALT may be as low as 21 IU/L for men and 17 IU/L for women when using metabolically healthy reference populations. 6, 7

When to Suspect Alternative Diagnoses:

• Autoimmune hepatitis: Should be suspected in all patients with elevated aminotransferases of unknown etiology, especially with elevated IgG levels and positive autoantibodies (ANA, SMA >1:80). 8 ALT levels are typically higher than AST in autoimmune hepatitis. 8

• Predominantly AST elevation: Consider non-hepatic causes including hemolysis, myopathy, thyroid disease, or strenuous exercise. 1

Management Based on Etiology

If initial workup supports NAFLD (negative viral serologies, metabolic risk factors present, no alternative explanation): 4

• Initiate lifestyle modification trial focusing on weight loss (7-10% body weight target)
• Address components of metabolic syndrome
• Repeat ALT and fibrosis assessment in 3-6 months
• If elevation persists despite lifestyle changes, consider hepatic ultrasonography and evaluation for uncommon causes

The key principle is that NAFLD represents a diagnosis of exclusion after ruling out viral hepatitis, significant alcohol use, medications, and hereditary liver diseases in the appropriate clinical context. 1, 4